Simultaneously, discussions have been initiated with the Food and Drug Administration for a health claim regarding the reduction of the risk of Type 2 Diabetes.
REVERSE-IT is an international, multicenter, randomized, double-blind, Phase IIB1 placebo-controlled study of 150 prediabetic individuals to determine the most efficient dose of Valedia.
The American part of the study will be conducted in in Miami, Florida and Chicago, Illinois.
Valedia, designed for prediabetics, improves insulin sensitivity and aims to reduce the risk of Type 2 Diabetes. In a Phase I/II clinical study, Valedia has demonstrated safety and early evidence of efficacy.
Valbiotis is committed to scientific innovation for preventing and fighting against metabolic diseases.
Its products are made for manufacturers in the agri-food and pharmaceutical industries.
The company particularly focuses on solutions to prevent type 2 diabetes, nonalcoholic steatohepatitis, obesity, and cardiovascular diseases.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients